Background: Microvascular bleeding after Cardiopulmonary bypass (CPB) is mainly due to consumption of clotting factors, platelets damage, and hyperfibrinolysis. Aprotinin, the only antifibrinolytic drug effective in preserving platelets, is no longer available; an alternative regimen based on pure antifibrinolytic drugs has been proposed, since hyperfibrinolysis is known to contribute both to clot lysis and platelet dysfunction. In this study the efficacy of two antifibrinolytic drugs, Tranexamic acid (TA) and epsilon-aminocaproic acid (EACA), was tested in patients undergoing cardiopulmonary bypass (CPB), for primary myocardial revascularization.
Methods: Forty-eight consecutive patients were randomized to receive prophylactically equipotent doses of EACA (group A) or TA (Group B). Platelet count, prothrombin time, fibrin digestion products, blood loss and transfusion requirements recorded after 6 and 24 hours from the end of surgery were compared.
Results: The two groups were comparable for length of CPB and numbers of grafts; no significant difference was observed in the coagulation parameters considered. Blood losses were less in group B (TA) than in group A (EACA), both at 6 and 24 hours after surgery; homologous blood transfused was also less in group B, but no difference was statistically significant. No adverse effect was observed.
Conclusions: In coronary patients, TA and EACA exhibit the same effects on blood loss and requirements after CPB; either drug can be safely used in cardiac surgery.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oral tranexamic acid for immediate use in major trauma: implications for mass casualty events.
Emerg Med J
January 2025
Academic Department of Military Emergency Medicine, Royal Centre for Defence Medicine, Birmingham, UK.
The early administration of tranexamic acid is recognised as significantly reducing mortality in traumatically injured patients with major haemorrhage, typically given via intravenous or intramuscular routes. In the context of mass casualty events, there may exist multiple traumatically injured casualties that would benefit from tranexamic acid, however, it's administration may be delayed through the need to establish intravenous access. Additionally, if the initial assessment of the traumatically injured casualty is undertaken by an individual who cannot administer intravenous or intramuscular medications, time to administration will be further delayed.
View Article and Find Full Text PDFMultimodal Artificial Intelligence Model for Prediction of Abdominal Aortic Aneurysm Shrinkage After Endovascular Repair ( the ART in EVAR study).
J Endovasc Ther
January 2025
Department of Vascular Surgery, Rijnstate, Arnhem, The Netherlands.
Purpose: The goal of the study described in this protocol is to build a multimodal artificial intelligence (AI) model to predict abdominal aortic aneurysm (AAA) shrinkage 1 year after endovascular aneurysm repair (EVAR).
Methods: In this retrospective observational multicenter study, approximately 1000 patients will be enrolled from hospital records of 5 experienced vascular centers. Patients will be included if they underwent elective EVAR for infrarenal AAA with initial assisted technical success and had imaging available of the same modality preoperatively and at 1-year follow-up (CTA-CTA or US-US).
Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome.
Stroke
January 2025
Departments of Medicine and Neurology, Melbourne Brain Centre @ The Royal Melbourne Hospital, University of Melbourne, AUSTRALIA.
There is limited data on ultra-early hematoma growth dynamics and its clinical relevance in primary intracerebral hemorrhage (ICH). We aimed to estimate the incidence of hematoma expansion (HE) within the hyperacute period of ICH, describe hematoma dynamics over time, investigate the associations between ultra-early HE and clinical outcomes after ICH, and assess the effect of tranexamic acid on ultra-early HE. We performed a planned secondary analysis of the STOP-MSU international multicenter randomized controlled trial.
View Article and Find Full Text PDFFrom research to practice: bridging the implementation gap on the use of tranexamic acid in total knee arthroplasty.
J Orthop Surg Res
January 2025
Central Coast Local Health District, Gosford, NSW, 2295, Australia.
Background: The use of intravenous tranexamic acid (TXA), an antifibrinolytic agent, has been shown to effectively reduce total blood loss and transfusion rates in total knee arthroplasty (TKA). The aim of this paper is to evaluate the implementation lag and clinical uptake of the use of TXA for primary TKA after publication of two landmark studies. Additionally, it assessed the efficacy of TXA use in TKA in reducing post-operative blood transfusions and hospital length of stay (LOS).
View Article and Find Full Text PDFEvaluating Surgeon-influenced Factors for Total Knee Arthroplasty Value-based Reimbursement.
J Am Acad Orthop Surg
January 2025
From the Rothman Orthopaedic Institute at Thomas Jefferson University Hospital, Philadelphia, USA (Sutton, Lizcano, Krueger, Courtney, and Purtill), and the Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, USA (Austin).
Introduction: Clinical outcome measures used under value-based reimbursement models require risk stratification of patient demographics and medical history. Only certain perioperative patient factors may be influenced by the surgeon. The study evaluated surgeon-influenced modifiable factors associated with achieving literature-defined KOOS score thresholds to serve as the foundation of the newly established alternative payment models for total knee arthroplasties (TKA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!